STAT+: Abivax has still not been acquired. What’s going on?
Biotech M&A activity is off the charts, yet the French drugmaker Abivax hasn't been picked up yet. There may be some explanations.
The story, originally published in Adam's Biotech Scorecard, reveals that Abivax, a French pharmaceutical company developing a potential blockbuster ulcerative colitis treatment, has yet to be acquired. Despite expectations that a $20 billion acquisition would occur by the end of a year, no transaction has materialized. This has left investors eagerly anticipating such a deal, causing frustration among Abivax's supporters.
The company's French origins has been cited as a potential reason for the lack of progress, with one explanation suggesting that the French are less productive in August. However, this theory remains unconfirmed as there is currently no insight into the intricacies of the acquisition process between Abivax and potential pharmaceutical buyers.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
